Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc. (OYST): 5 pipeline candidates · ~7 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.5 months
D/E -5.92 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Oyster Point Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$68.8M
Quarterly Burn
$36.0M
Runway
6.5 mo
Revenue
$5.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| oc-01 | Phase 2 |
| oc-02 | Phase 2 |
| oc-101 | Preclinical |
| tyrvaya | Approved |
| tyrvaya nasal pump | Phase 4 |
Frequently asked questions
How many drug candidates are in Oyster Point Pharma, Inc.'s pipeline?
Oyster Point Pharma, Inc. (OYST) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Oyster Point Pharma, Inc.'s lead drug candidate?
Oyster Point Pharma, Inc.'s most advanced tracked candidate is oc-01 (Phase 2) for Neurotrophic keratopathy (NK).
What is Oyster Point Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Oyster Point Pharma, Inc. has approximately 6.5 months of cash runway.
Who is the CEO of Oyster Point Pharma, Inc.?
Jeffrey Nau, Ph.D. is the chief executive officer of Oyster Point Pharma, Inc. (OYST).
Get the full picture on Oyster Point Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.